Boston Scientific Corporation Earnings Recaps
Q2 2026
Aug 1, 2026
Boston Scientific's shares were essentially unchanged (-0.1%) as the quarter showed steady organic sales growth and solid margins, but the market digested cautious guidance revisions driven by softness in WATCHMAN and electrophysiology (EP) segments.
Key takeaways
- Q2 organic revenue grew 7%, driven by Interventional Cardiology, Endoscopy, and Neuromodulation, within prior full-year guidance range.
- Adjusted EPS of $0.86 rose 15%, aided by favorable tax outcomes, and operating margin was healthy at 28.4%.
- Guidance trimmed: full-year organic growth now expected at 5%-6%, below previous midpoint; adjusted EPS growth moderation reflected in narrowed $3.28-$3.32 range.
- Key headwinds in WATCHMAN (clinical evidence impacting referrals) and EP (unexpected share loss in U.S.) pressured outlook; these segments weigh on near-term growth.
- Restructuring plan announced to deliver $500 million in run-rate savings by 2029, aiming to offset pressures and underpin improved growth in 2028 and beyond.
Q1 2026
Apr 22, 2026
Boston Scientific delivered a solid Q1 with 9.4% organic sales growth and adjusted EPS at the high end of guidance, though the company has lowered its full-year outlook due to unexpected headwinds affecting growth trajectories.
Key takeaways
- Q1 organic revenue exceeded guidance at 9.4%, with adjusted EPS of $0.80, growing 6%.
- Full-year 2026 organic growth guidance reduced to 6.5–8% from prior expectations, reflecting unanticipated challenges.
- U.S. region showed robust 11% growth, driven by multiple business units; EMEA and Asia Pacific experienced slower and strong growth respectively.
- Growth in segments like Neuromodulation remained strong at 15%, while Urology faced challenges with only 1% growth amid product gaps and market disruptions.
- The company remains committed to strategic investments and innovation, despite near-term headwinds impacting some product categories and regional markets.
Q3 2025
Oct 23, 2025
Boston Scientific's Q3 2025 results surpassed expectations with 19% operational sales growth and a 15% increase in organic sales, driven by strong performances in Cardiovascular and MedSurg segments.
Key takeaways
- Adjusted EPS rose 19% to $0.75, exceeding guidance and signaling robust operational efficiency.
- U.S. operations experienced exceptional growth at 27%, while the Asia-Pacific region also performed strongly with a 17% increase.
- Although EMEA saw a 2% decline due to temporary headwinds, underlying growth was strong, indicating resilience in key markets.
- Full-year adjusted EPS guidance raised to $3.02 to $3.04, reflecting the company's confidence in continued above-market growth.
- Upcoming acquisition of Nalu Medical poised to enhance Boston Scientific's portfolio in the interventional pain market, expected to close in H1 2026.